In the global pharmaceutical landscape of 2026, the circulation of substandard or counterfeit medicines remains a major challenge for health authorities and patients. Among the most essential—yet also the most vulnerable to non-compliance—medicines, albendazole plays a central role. Whether in...
Read more
In the global pharmaceutical landscape of 2026, the circulation of...